Zhifei Longcom Biopharmaceutical (PRC) has recognized Uzbekistan as a co-author in the development of a ZF-2001 coronavirus vaccine, the Anti-Coronavirus Commission officials said at a meeting.
From now on, together with Uzbek pharmacists, the drug will be produced under the brand ZF-UZ-VAC 2001. The Chinese developers, having studied the activities of a number of pharmaceutical companies, chose Jurabek Laboratories LLC as a partner.
The meeting also discussed the issue of the emergency use authorization of ZF-UZ-VAC 2001, taking into account the successful conduct of the third clinical trials in Uzbekistan.
Zhifei Longcom, in cooperation with Uzbek pharmaceutical companies, is capable of producing up to 300 million doses of the vaccine this year, which will provide the country with the required amount and begin mass vaccination before the year-end.
Following the meeting, the special commission decided to submit to the Legislative Chamber for discussion the issue of purchasing 1 million doses of the ZF-UZ-VAC 2001 vaccine and start voluntary mass vaccination.
Additionally, negotiations are underway with the Global Alliance for Vaccines and Immunization (GAVI) on the free supply of about 2.5 million doses of Astra-Zeneca vaccine (Oxford, UK) to Uzbekistan. Uzbekistan could receive the first batch of this vaccine of 800 thousand doses in March.
Uzbekistan has also certified and approved for mass use the Sputnik V vaccine, developed by the Russian Scientific Center named after Gamaleya.
